Evaluation shows an association between biologic therapies and demyelinating events in IBD and rheumatologic disorders, suggesting concern for patient safety.
To evaluate the association between biologic therapies for rheumatologic disorders and inflammatory bowel diseases (IBD) and the occurrence of demyelinating adverse events using the FDA Adverse Event Reporting System (FAERS).
No takes yet. Share an insight, caveat, or question.
Almadaoji et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: